חיפוש
63 מחקרים תואמים למסננים אלה. מציג 26–50 מתוך 63 מחקרים
| מספר רישום | מחקר | מצב | שלב | גיוס | אתרים / מדינות | שנת התחלה | עודכן לאחרונה | פעולות |
|---|---|---|---|---|---|---|---|---|
| NCT05624996 | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or targeted therapy with osimertinib) versus the usual treatment alone… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 477 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 474יעד | 477 / 2 | 2023 | 17 באוג׳ 2026 | |
| NCT07293247 | A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining lymph node… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 125 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 2 | 164יעד | 125 / 1 | 2026 | 3 בנוב׳ 2026 | |
| NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and di… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 317 מרכזים בסך הכול | מגייס | שלב 3 | 1,530יעד | 317 / 31 | 2024 | 18 בנוב׳ 2026 | |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 751 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | 2,900יעד | 751 / 1 | 2022 | 4 בנוב׳ 2026 | ||
| NCT04181060 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signa… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 604 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 300יעד | 604 / 1 | 2020 | 4 בנוב׳ 2026 | |
| NCT06545955 | A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firaden… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 81 מרכזים בסך הכול | מגייס | שלב 3 | 250יעד | 81 / 8 | 2024 | 12 בנוב׳ 2026 | |
| NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immun… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Kingman, Kansas, United States — במרחק 28 ק"מ · 1,151 מרכזים בסך הכול | מגייס | שלב 3 | 1,210יעד | 1,151 / 2 | 2020 | 12 בנוב׳ 2026 | |
| NCT05946213 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a pa… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 436 מרכזים בסך הכול | מגייס | שלב 3 | 1,500יעד | 436 / 5 | 2023 | 23 באוק׳ 2026 | |
| NCT07097142 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or mitomycin and 5-fluorouracil for the treatment of patients… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 259 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 486יעד | 259 / 2 | 2025 | 23 באוק׳ 2026 | |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study com… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Kingman, Kansas, United States — במרחק 28 ק"מ · 776 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 2 / שלב 3 | 626יעד | 776 / 47 | 2020 | 19 בנוב׳ 2026 | |
| NCT06056830 | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases. ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 34 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 383יעד | 34 / 3 | 2023 | 11 בספט׳ 2026 | |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blo… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Kingman, Kansas, United States — במרחק 28 ק"מ · 582 מרכזים בסך הכול | מגייס | שלב 2 | 314יעד | 582 / 2 | 2019 | 18 בנוב׳ 2026 | |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell g… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Kingman, Kansas, United States — במרחק 28 ק"מ · 647 מרכזים בסך הכול | מגייס | שלב 3 | 1,450יעד | 647 / 2 | 2021 | 16 בנוב׳ 2026 | |
| NCT04729114 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their canc… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 25 מרכזים בסך הכול | מגייס | שלב 1 | 174יעד | 25 / 2 | 2021 | 4 בפבר׳ 2026 | |
| NCT07206056 | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC). ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 35 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 1 / שלב 2 | 188יעד | 35 / 14 | 2025 | 9 באוק׳ 2026 | |
| NCT06533644 | A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study. ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 23 מרכזים בסך הכול | מגייס | שלב 2 | 91יעד | 23 / 1 | 2025 | 23 ביוני 2026 | |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will deter… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Kingman, Kansas, United States — במרחק 28 ק"מ · 1,229 מרכזים בסך הכול | מגייס | שלב 2 / שלב 3 | 10,000יעד | 1,229 / 1 | 2019 | 18 במאי 2026 | |
| NCT06937177 | Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newly diagnosed, advanced, unresectable colorectal cancer (CRC) o… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 26 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 2 | 120יעד | 26 / 2 | 2025 | 15 ביולי 2026 | |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 279 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | 75,000יעד | 279 / 6 | 2015 | 19 בנוב׳ 2026 | ||
| NCT06906562 | A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started to other places in the body… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 109 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 2 | 40יעד | 109 / 1 | 2025 | 17 בפבר׳ 2026 | |
| NCT07225946 | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxe… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 165 מרכזים בסך הכול | מגייס | שלב 3 | 800יעד | 165 / 17 | 2025 | 3 בנוב׳ 2026 | |
| NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CML-CP Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure c… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 163 מרכזים בסך הכול | מגייס | שלב 3 | 333יעד | 163 / 16 | 2024 | 15 בספט׳ 2026 | |
| NCT06510374 | Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC) ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 119 מרכזים בסך הכול | מגייס | שלב 3 | 454יעד | 119 / 10 | 2024 | 12 בנוב׳ 2026 | |
| NCT04852887 | De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy. ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Wichita, Kansas, United States — במרחק 43 ק"מ · 832 מרכזים בסך הכול · פרטי קשר זמינים | מגייס | שלב 3 | 1,670יעד | 832 / 4 | 2021 | 23 באפר׳ 2026 | |
| NCT06880055 | Shield Post-Approval Study Protocol The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC usi… ✓ יצירת קשר✗ נתבע המרכז הקרוב ביותר: Hutchinson, Kansas, United States — במרחק 36 ק"מ · 83 מרכזים בסך הכול | מגייס | 3,375יעד | 83 / 1 | 2025 | 12 בנוב׳ 2026 |